Zhiwei Zheng
7PUBLICATIONS
1CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Jun 13, 2025
Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.Zhiwei Zheng, Huide Zhu, Ling Fang
|Mar 25, 2025
Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis.Zhiwei Zheng, Huide Zhu, Ling Fang
|Dec 11, 2024
Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.Hongfu Cai, Jingwen Lin, Huide Zhu
|Dec 15, 2023
First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis.Zhiwei Zheng, Ling Fang, Hongfu Cai
|Nov 29, 2023
Cemiplimab combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis.Gaofeng Zhu, Hongfu Cai, Zhiwei Zheng
|Jul 04, 2023
Cost-effectiveness analysis of serplulimab as first-line treatment for advanced esophageal squamous cell carcinoma.Zhiwei Zheng, Ling Fang, Hongfu Cai
Pageof 2
